Xeris Biopharma Holdings, Inc.
XERS Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$10.20
KIRA · Stoqly’s AI analyst, in plain words
- Xeris Biopharma Holdings, Inc. had $292M of revenue in fiscal 2025, up 43.7% on the year before. Over five years, revenue changed +70.2% a year on average.
- Its operating margin was 8.5%, up 25.1 pts: of every 100 in sales, about 9 is left after running the business.
- Xeris Biopharma Holdings, Inc. made $0.6M of net profit in fiscal 2025.
- Xeris Biopharma Holdings, Inc. owes $109M more than it holds in cash, about 4.2 years of operating profit.
Market cap
$1.8B
P/E
—
Revenue
$292M
Net income
$0.6M
Free cash flow
—
Operating margin
8.5%
Xeris Biopharma Holdings, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+43.7%
Yes. Sales grew 43.7% last year.
Does it make a profit?
0.2%
A little. It keeps 0.2% of every sale as profit.
Is debt under control?
4.2x
Heavy. Repaying its debt would take 4.2 years of operating profit.
How healthy are the accounts?
7 / 8
Solid. It passes 7 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Xeris Biopharma Holdings, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 2, 2026
- Legal name
- Xeris Biopharma Holdings, Inc.
- CIK
- 0001867096
Xeris Biopharma Holdings, Inc. · XERS
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $49.6M | $110M | $164M | $203M | $292M |
| Revenue growth | 142.7% | 122.3% | 48.7% | 23.9% | 43.7% |
| Operating margin | −232.2% | −74.3% | −26.8% | −16.6% | 8.5% |
| Net income | −$123M | −$94.7M | −$62.3M | −$54.8M | $0.6M |
| Net margin | −247.5% | −85.9% | −38.0% | −27.0% | 0.2% |
| Diluted EPS | −$1.55 | −$0.70 | −$0.45 | −$0.37 | $0.00 |
| Cash | |||||
| Cash from operations | −$95.5M | −$103M | −$47.0M | −$37.0M | $28.6M |
| Capital expenditure | $1.1M | — | — | — | — |
| Free cash flow | −$96.6M | — | — | — | — |
| FCF margin | −194.8% | — | — | — | — |
| Share count change | 85.3% | 71.6% | 1.5% | 6.6% | 17.7% |
| Debt and strength | |||||
| Cash and short-term investments | $102M | $122M | $72.5M | $71.6M | $111M |
| Debt incl. finance leases | $88.1M | $187M | $191M | $232M | $220M |
| Shareholders' equity | $95.2M | $45.2M | −$6.8M | −$29.6M | $13.7M |
| Net debt / EBITDA | — | — | — | — | 4.2x |
| Current ratio | 1.8x | 2.5x | 1.6x | 1.7x | 2.2x |
| Interest coverage | −16.0x | −5.8x | −1.7x | −1.1x | 0.9x |
| Returns and quality | |||||
| Return on capital | −112.5% | −58.7% | −31.1% | −20.3% | 20.2% |
| Return on equity | −190.3% | −134.8% | −324.2% | — | — |
| Piotroski F-score | 4 | 3 | 3 | 4 | 7 |
| Altman Z'' | −5.6 | −4.5 | −5.9 | −6.2 | −3.0 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$5.4M
9 insiders
Of sales under plans
82%
$4.4M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Xeris Biopharma Holdings, Inc. · XERS
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $10.20 a share, the company is worth $1.8B.
Source: SEC EDGAR XBRL filings (CIK 0001867096). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.